Assembly Biosciences (NASDAQ: ASMB) recently received a number of ratings updates from brokerages and research firms:
- 9/1/2026 – Assembly Biosciences was given a new $53.00 price target by Mizuho.
- 9/1/2026 – Assembly Biosciences is now covered by UBS Group AG. They set a “buy” rating and a $52.00 price target on the stock.
- 9/1/2026 – Assembly Biosciences is now covered by UBS Group AG. They set a “buy” rating and a $52.00 price target on the stock.
- 9/1/2026 – Assembly Biosciences had its price target lowered by Mizuho from $53.00 to $45.00. They now have an “outperform” rating on the stock.
- 8/20/2026 – Assembly Biosciences was upgraded by Zacks Research from “hold” to “strong-buy”.
- 8/18/2026 – Assembly Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Assembly Biosciences, Inc is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control.
The company’s pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle.
Featured Stories
- Five stocks we like better than Assembly Biosciences
- Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
- The Ultimate Cyber Shield: CrowdStrike Rises Past $235
- Palantir Just Told Wall Street Where AI Infrastructure Is Headed
- Homebuilders Are Down for the Year, Is Wall Street in Denial?
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
